TP53 and neoplasm: However, in the prostate cancer cell lines 22Rv1 and LNCaP, where FOXO1 has been reported to act in a tumor-suppressive manner (5), depletion of FOXO1 did not alter MDM2 and p53 expression (Fig. S2, C and D).